A capture-sequencing strategy identifies IRF8, EBF1, and APRIL as novel IGH fusion partners in B-cell lymphoma

Blood

Volumn 122, Issue 5, 2013, Pages 726-733

  Bouamar, Hakim ^a   Abbas, Saman ^a   Lin, An Ping ^a   Wang, Long ^a   Jiang, Daifeng ^a   Holder, Kenneth N ^b   Kinney, Marsha C ^b   Hunicke Smith, Scott ^c   Aguiar, Ricardo C T ^a,d  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b University of Texas Health Science Center at San Antonio   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d San Antonio Cancer Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN APRIL FUSION PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN BCL 2 FUSION PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN BCL 6 FUSION PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN CCND1 FUSION PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN EBF1 FUSION PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN INTERFERON REGULATORY FACTOR 8 FUSION PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN MYC FUSION PROTEIN; UNCLASSIFIED DRUG; APRIL PROTEIN; EBF1 PROTEIN, HUMAN; IMMUNOGLOBULIN HEAVY CHAIN; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERFERON REGULATORY FACTOR; ONCOPROTEIN; TNFSF13 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER PATIENT; CANCER RESISTANCE; CARCINOGENESIS; CONTROLLED STUDY; DIFFUSE LARGE B CELL LYMPHOMA; DOWN REGULATION; ECTOPIC EXPRESSION; GENE EXPRESSION; GENE LOCUS; GENE REARRANGEMENT; GENE SEQUENCE; GENE TRANSLOCATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; STABLE EXPRESSION; UPREGULATION; B CELL LYMPHOMA; CELL STRAIN HEK293; GENE LIBRARY; GENETICS; HIGH THROUGHPUT SEQUENCING; METHODOLOGY; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; TUMOR CELL LINE; VALIDATION STUDY;

BASE SEQUENCE; CELL LINE, TUMOR; GENE LIBRARY; GENE REARRANGEMENT, B-LYMPHOCYTE; HEK293 CELLS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; INTERFERON REGULATORY FACTORS; LYMPHOMA, B-CELL; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, FUSION; TRANS-ACTIVATORS; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13; VALIDATION STUDIES AS TOPIC;

EID: 84886384338     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-04-495804     Document Type: Article

References (37)

1. Willis TG, Dyer MJ. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood. 2000;96(3):808-822.
2. Küppers R, Dalla-Favera R. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene. 2001;20(40):5580-5594.
3. Sandberg AA, Meloni-Ehrig AM. Cytogenetics and genetics of human cancer: methods and accomplishments. Cancer Genet Cytogenet. 2010;203(2):102-126.
4. Shaffer LG, Schultz RA, Ballif BC. The use of new technologies in the detection of balanced translocations in hematologic disorders. Curr Opin Genet Dev. 2012;22(3):264-271.
5. Li C, Kim SW, Rai D, et al. Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma. Blood. 2009;113(26): 6681-6690.
6. Rai D, Kim SW, McKeller MR, Dahia PL, Aguiar RC. Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis. Proc Natl Acad Sci USA. 2010;107(7):3111-3116.
7. DeKosky BJ, Ippolito GC, Deschner RP, et al. High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire. Nat Biotechnol. 2013;31(2):166-169.
8. Yin CC, Luthra R. Molecular Detection of t(14;18)(q32;q21) in Follicular Lymphoma. Methods Mol Biol. 2013;999:203-209.
9. Batstone PJ, Goodlad JR. Efficacy of screening the intermediate cluster region of the bcl2 gene in follicular lymphomas by PCR. J Clin Pathol. 2005; 58(1):81-82.
10. Kim SW, Ramasamy K, Bouamar H, Lin AP, Jiang D, Aguiar RC. MicroRNAs miR-125a and miR-125b constitutively activate the NF-kB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl Acad Sci USA. 2012;109(20): 7865-7870.
11. Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009;114(11):2273-2279.
12. Bernicot I, Douet-Guilbert N, Le Bris MJ, Herry A, Morel F, De Braekeleer M. Molecular cytogenetics of IGH rearrangements in non-Hodgkin B-cell lymphoma. Cytogenet Genome Res. 2007; 118(2-4):345-352.
13. Nanjangud G, Rao PH, Hegde A, et al. Spectral karyotyping identifies new rearrangements, translocations, and clinical associations in diffuse large B-cell lymphoma. Blood. 2002;99(7): 2554-2561.
14. Parsyan A, Svitkin Y, Shahbazian D, Gkogkas C, Lasko P, Merrick WC, Sonenberg N. mRNA helicases: the tacticians of translational control. Nat Rev Mol Cell Biol. 2011;12(4):235-245.
15. Dillon SR, Gross JA, Ansell SM, Novak AJ. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov. 2006; 5(3):235-246.
16. Busslinger M. Transcriptional control of early B cell development. Annu Rev Immunol. 2004;22:55-79.
17. Nutt SL, Kee BL. The transcriptional regulation of B cell lineage commitment. Immunity. 2007;26(6): 715-725.
18. Lin YC, Jhunjhunwala S, Benner C, et al. A global network of transcription factors, involving E2A, EBF1 and Foxo1, that orchestrates B cell fate. Nat Immunol. 2010;11(7):635-643.
19. Kikuchi H, Nakayama M, Takami Y, Kuribayashi F, Nakayama T. EBF1 acts as a powerful repressor of Blimp-1 gene expression in immature B cells. Biochem Biophys Res Commun. 2012; 422(4):780-785.
20. Walker BA, Wardell CP, Johnson DC, et al. Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood. 2013;121(17):3413-3419.
21. Bitterman PB, Polunovsky VA. Attacking a nexus of the oncogenic circuitry by reversing aberrant eIF4F-mediated translation. Mol Cancer Ther. 2012;11(5):1051-1061.
22. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood. 1998;92(9):3025-3034.
23. Wang H, Morse HC III. IRF8 regulates myeloid and B lymphoid lineage diversification. Immunol Res. 2009;43(1-3):109-117.
24. Lee CH, Melchers M, Wang H, et al. Regulation of the germinal center gene program by interferon (IFN) regulatory factor 8/IFN consensus sequence-binding protein. J Exp Med. 2006; 203(1):63-72.
25. Martinez A, Pittaluga S, Rudelius M, et al. Expression of the interferon regulatory factor 8/ICSBP-1 in human reactive lymphoid tissues and B-cell lymphomas: a novel germinal center marker. Am J Surg Pathol. 2008;32(8):1190-1200.
26. Mandelbaum J, Bhagat G, Tang H, et al. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell. 2010;18(6):568-579.
27. Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360): 298-303.
28. Zhang J, Grubor V, Love CL, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA. 2013;110(4):1398-1403.
29. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127): 1546-1558.
30. Medvedovic J, Ebert A, Tagoh H, Busslinger M. Pax5: a master regulator of B cell development and leukemogenesis. Adv Immunol. 2011;111: 179-206.
31. Heltemes-Harris LM, Willette MJ, Ramsey LB, et al. Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia. J Exp Med. 2011;208(6): 1135-1149.
32. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007; 446(7137):758-764.
33. Poppe B, De Paepe P, Michaux L, et al. PAX5/IGH rearrangement is a recurrent finding in a subset of aggressive B-NHL with complex chromosomal rearrangements. Genes Chromosomes Cancer. 2005;44(2): 218-223.
34. Cozma D, Yu D, Hodawadekar S, et al. B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling. J Clin Invest. 2007;117(9):2602-2610.
35. Pasqualucci L, Neumeister P, Goossens T, Nanjangud G, Chaganti RS, Küppers R, Dalla-Favera R. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001; 412(6844):341-346.
36. Jiang Y, Soong TD, Wang L, Melnick AM, Elemento O. Genome-wide detection of genes targeted by non-Ig somatic hypermutation in lymphoma. PLoS ONE. 2012;7(7):e40332.
37. Vilagos B, Hoffmann M, Souabni A, et al. Essential role of EBF1 in the generation and function of distinct mature B cell types. J Exp Med. 2012;209(4):775-792.